Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs TrueMe

GoodRx
Graded #122

Higher grade

vs+2
TrueMe
Graded #169

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 67.6/100, but only just.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. TrueMe is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +18
80
62
Dose & formulationTrueMe +7
70
77
Clinical oversightTrueMe +9
69
78
Labs & monitoringTrueMe +1
51
52
FulfillmentEven
81
81
Contract termsGoodRx +10
55
45
GoodRx · left barTrueMe · right bar

The numbers

MetricGoodRxTrueMe
WeighScore69.6/10067.6/100
GradeCC
Scorecard rank#122#169
SemaglutideNot disclosed$159/mo (compounded)
Tirzepatide$299/mo (brand Zepbound)$189/mo (compounded)
CoverageAll 50 states6 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
GoodRx

Graded #122 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
TrueMe

Graded #169 · C

Strengths

  • One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
  • Same price at every dose, so the cost does not climb as a provider titrates the dose upward
  • Full pricing is published up front — no intake form is required before you can see what you will pay
  • Carries a genuine LegitScript-issued seal (ID 50205625) that resolves on LegitScript's own asset host
  • Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas

Where it loses points

  • Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
  • Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
  • You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
  • The 3-month rates ($119 and $139/mo) are a single upfront charge of $357 or $417, not a lower monthly plan
  • A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard